Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease

Cavalon and its collaborators have discovered in an analysis of a major NIH-funded Phase III clinical trial in Parkinson’s disease that patients who cleared a candidate medicine more slowly manifested signs of slower disease progression